Imprimis Pharmaceuticals Looks to Expand its Ophthalmology Portfolio with LessDrops™
Proprietary topical compounded formulations offer the promise of significantly reducing the number of patient eye drop administrations as well as the high cost of eye drops typically required for traditional treatment
Results of an investigator-initiated evaluation of the company’s Pred-Moxi and Tri-Moxi topical eye drops for patients following LASIK surgery expected to be announced by end of January 2015
/PRNewswire/ — Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today announced its plans to introduce proprietary triamcinolone acetonide and moxifloxacin hydrochloride (Tri-Moxi) and prednisolone acetate and moxifloxacin hydrochloride (Pred-Moxi) combination eye drop formulations for patients following laser refractive surgery, including LASIK and photorefractive keratectomy (PRK) surgery, cataract and other ocular surgeries.
Curated from Imprimis Pharmaceuticals Looks to Expand its Ophthalmology Portfolio with LessDrops™